Get the Stockscreener App
85.28
1.54%
1.305
Edwards Lifesciences Corp stock is traded at $85.28, with a volume of 1.67M.
It is up +1.54% in the last 24 hours and up +1.33% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$83.98
Open:
$84.12
24h Volume:
1.67M
Relative Volume:
0.38
Market Cap:
$49.49B
Revenue:
$5.88B
Net Income/Loss:
$1.34B
P/E Ratio:
36.31
EPS:
2.3489
Net Cash Flow:
$799.60M
1W Performance:
-1.71%
1M Performance:
+1.33%
6M Performance:
+9.53%
1Y Performance:
+14.92%
1-Day Range:
$83.98
$85.96
1-Week Range:
$83.60
$87.19
52-Week Range:
$65.94
$87.40
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
85.29 | 48.73B | 5.88B | 1.34B | 799.60M | 2.3489 |
|
ABT
Abbott Laboratories
|
124.64 | 217.86B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.50 | 146.12B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
363.24 | 139.95B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
102.13 | 130.73B | 34.76B | 4.79B | 5.21B | 3.7017 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Edwards Lifesciences (EW) Revises FY25 Revenue Projection Upward - GuruFocus
Edwards Lifesciences Reiterates 2025 Guidance; 2026 Forecast Issued - MarketScreener
Edwards Lifesciences reaffirms strategy for sustainable, differentiated growth at annual investor conference - MarketScreener
Edwards Lifesciences (NYSE: EW) targets 2026 EPS of $2.80-$2.95 with TMTT up 35%-45% - Stock Titan
Edwards Lifesciences Corporation $EW Shares Sold by Northwestern Mutual Wealth Management Co. - MarketBeat
Groupe la Francaise Purchases 16,834 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Is Edwards Lifesciences Corporation (EWL) stock undervalued after correctionJuly 2025 PreEarnings & Reliable Intraday Trade Alerts - Newser
Edwards Lifesciences stock maintains Neutral rating at UBS ahead of Investor Day By Investing.com - Investing.com
OMERS ADMINISTRATION Corp Boosts Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
What is the fair value estimate for Edwards Lifesciences Corporation (EWL) stock in 2025July 2025 Review & Technical Buy Zone Confirmation - Newser
American Century Companies Inc. Sells 1,049,818 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW) Stock Review: Q3 Earnings & 2025 PerformanceNews and Statistics - IndexBox
Is Edwards Lifesciences Corporation (EWL) stock a safe buy pre earnings2025 Year in Review & Expert-Curated Trade Recommendations - Newser
How Is Edwards Lifesciences’ Stock Performance Compared to Other Medical Device Stocks? - Barchart.com
Will Edwards Lifesciences Corporation (EWL) stock maintain strong growthJuly 2025 Pullbacks & Safe Capital Growth Plans - Newser
New York State Common Retirement Fund Sells 29,484 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Norges Bank Takes Position in Edwards Lifesciences Corporation $EW - MarketBeat
Quadrant Capital Group LLC Grows Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Elevation Point Wealth Partners LLC Decreases Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - Finviz
State Board of Administration of Florida Retirement System Sells 3,837 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Korea Investment CORP Has $36.33 Million Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Laurel Wealth Advisors LLC Raises Position in Edwards Lifesciences Corporation $EW - MarketBeat
First National Advisers LLC Buys 9,644 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Edwards Lifesciences Corporatio (EW) Stock forecasts - Yahoo Finance UK
Steward Partners Investment Advisory LLC Has $6.86 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Stock Position Raised by United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund - MarketBeat
Northwest & Ethical Investments L.P. Boosts Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
69,100 Shares in Edwards Lifesciences Corporation $EW Bought by Employees Retirement System of Texas - MarketBeat
Edwards Lifesciences (NYSE:EW) Sets New 12-Month HighShould You Buy? - MarketBeat
Russell Investments Group Ltd. Raises Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Rhenman & Partners Asset Management AB Takes $4.30 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
RiverPark Advisors LLC Has $795,000 Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Angiostomy Cannula Market to Get an Explosive Growth | Edwards - openPR.com
Edwards Lifesciences' (NYSE:EW) investors will be pleased with their 20% return over the last year - Yahoo Finance
Elo Mutual Pension Insurance Co Reduces Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences stock reaches 52-week high at 87.25 USD By Investing.com - Investing.com Nigeria
Edwards Lifesciences stock reaches 52-week high at 87.25 USD - Investing.com India
BTIG Research Reiterates "Buy" Rating for Edwards Lifesciences (NYSE:EW) - MarketBeat
Edwards Lifesciences Corporation $EW Stock Holdings Boosted by Edmond DE Rothschild Holding S.A. - MarketBeat
Edwards Lifesciences Lifts Outlook After Topping Expectations - Finimize
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences (EW) Analyst Rating Reiterates Buy with $10 - GuruFocus
Journey Strategic Wealth LLC Takes Position in Edwards Lifesciences Corporation $EW - MarketBeat
Rhumbline Advisers Sells 34,159 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Mediolanum International Funds Ltd - MarketBeat
Edwards Lifesciences Corporation (EWLS.VI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Legal & General Group Plc Sells 269,910 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Swiss National Bank Raises Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Handelsbanken Fonder AB Buys 139,909 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):